



## **The Impact of Pharmacist Involvement in Therapeutic Drug Monitoring on Clinical Outcomes**

**Alanazi, Meshari Jazaa O<sup>1\*</sup>, Madallah Sayer Iswid Alruwaili<sup>2</sup>, Turki Khalid Obaid Alhamed<sup>3</sup>, Mashaal Duhaim Alanazi<sup>4</sup>, Rimah Shuwaysh Alruwaili<sup>5</sup>, Ayed Hamad Ayed Alanazi<sup>6</sup>, Alhazmi, Thuraya Falah K<sup>7</sup>, Mubarak Abdulaziz Aldossari<sup>8</sup>, Khaled Bandar Mohsen Al Otaibi<sup>9</sup>, Rowida Ayyaf Alayyaf<sup>10</sup>, Khalid Ali Mohammed Alamri<sup>11</sup>**

<sup>1</sup>Pharmacy Technician – Jadidah Arar Hospital, Northern Borders Health Cluster, Ministry of Health, Arar, Northern Borders Region, Saudi Arabia

\* **Corresponding Author Email:** mesharija@moh.gov.sa - **ORCID:** 0000-0002-1047-7850

<sup>2</sup>Pharmacy Technician – Maternity and Children Hospital, Northern Borders Health Cluster, Ministry of Health, Arar, Northern Borders Region, Saudi Arabia

**Email:** masaalruwaili@moh.gov.sa - **ORCID:** 0000-0002-1047-0050

<sup>3</sup>Pharmacy Assistant – Supply Chain Management Administration, Hail Health Cluster, Ministry of Health, Hail, Hail Region, Saudi Arabia

**Email:** talhamed@moh.gov.sa - **ORCID:** 0000-0002-2047-0050

<sup>4</sup>Pharmacy Technician – Prince Abdulaziz bin Musa'ed Hospital, Northern Borders Health Cluster, Ministry of Health, Arar, Northern Borders Region, Saudi Arabia

**Email:** Mishaelda@moh.gov.sa - **ORCID:** 0000-0002-3047-0050

<sup>5</sup>Pharmacy Technician – Assistant Administration for Performance and Compliance, Branch of the Ministry of Health, Ministry of Health, Sakaka, Al-Jouf Region, Saudi Arabia

**Email:** msalrowely@moh.gov.sa - **ORCID:** 0000-0002-4047-0050

<sup>6</sup>Pharmacy Technician – Northern Medical Tower, Northern Borders Health Cluster, Ministry of Health, Arar, Northern Borders Region, Saudi Arabia

**Email:** Ayhalenazi@moh.gov.sa - **ORCID:** 0000-0002-5047-0050

<sup>7</sup>Pharmacy Technician – West Turaif Primary Health Care Center, Northern Borders Health Cluster, Ministry of Health, Turaif, Northern Borders Region, Saudi Arabia

**Email:** t.hhh.1403@gmail.com - **ORCID:** 0000-0002-6047-0050

<sup>8</sup>Pharmacy Technician – Licensing Administration, General Directorate of Health Affairs, Ministry of Health, Al Madinah Al Munawwarah, Al Madinah Region, Saudi Arabia

**Email:** maaldosary@moh.gov.sa - **ORCID:** 0000-0002-7047-0050

<sup>9</sup>Pharmacy Technician – Al Rosan Primary Health Care Center, Dawadmi General Hospital, Third Riyadh Health Cluster, Ministry of Health, Dawadmi, Riyadh Region, Saudi Arabia

**Email:** khbaalotaibi@moh.gov.sa - **ORCID:** 0000-0002-8047-0050

<sup>10</sup>Pharmacy Technician – Maternity and Children Hospital, Al-Jouf Health Cluster, Ministry of Health, Sakaka, Al-Jouf Region, Saudi Arabia

**Email:** rodina\_mr@hotmail.com - **ORCID:** 0000-0002-9047-0050

<sup>11</sup>Pharmacist – King Abdulaziz Specialist Hospital, Taif Health Cluster, Ministry of Health, Taif, Makkah Region, Saudi Arabia

**Email:** a17@hotmail.cz - **ORCID:** 0000-0002-8847-0050

## **Article Info:**

**DOI:** 10.22399/ijcesen.4674

**Received :** 01 July 2024

**Accepted :** 30 July 2024

## **Keywords**

Clinical Pharmacist,  
Therapeutic Drug Monitoring  
(TDM),  
Clinical Outcomes,  
Pharmacokinetics,  
Personalized Dosing,  
Narrow Therapeutic Index

## **Abstract:**

The integration of pharmacists into the Therapeutic Drug Monitoring (TDM) process has a profoundly positive impact on clinical outcomes, transforming it from a reactive laboratory test into a proactive, patient-centric management strategy. By applying specialized expertise in pharmacokinetics and pharmacotherapy, pharmacists ensure accurate interpretation of drug levels within the full clinical context—considering factors like timing, organ function, and drug interactions. This leads to precise, individualized dosing recommendations for medications with a narrow therapeutic index, such as aminoglycosides, vancomycin, and immunosuppressants. The direct clinical results are measurably improved: enhanced therapeutic efficacy, a significant reduction in drug-related toxicity and adverse events, and improved patient adherence through education. Furthermore, pharmacist-led TDM fosters stronger interdisciplinary collaboration and generates substantial healthcare system benefits by preventing costly complications, optimizing resource use, and shortening hospital stays, thereby elevating the overall quality, safety, and efficiency of patient care.

## **1. Introduction**

The landscape of modern healthcare is characterized by an ever-increasing complexity of therapeutic regimens, particularly for patients with chronic, severe, or complicated medical conditions. The paradigm of "one-size-fits-all" in pharmacotherapy has been conclusively overturned by our deepening understanding of interpatient variability in drug response. This variability, stemming from a confluence of genetic, physiological, pathological, and environmental factors, can lead to suboptimal therapeutic outcomes, including therapeutic failure or the emergence of dose-related adverse drug reactions (ADRs) [1]. In this intricate context, the pursuit of personalized or precision medicine has emerged as a cardinal objective, aiming to tailor drug therapy to the individual characteristics of each patient to maximize efficacy and minimize harm.

Therapeutic Drug Monitoring (TDM) stands as a cornerstone of this personalized approach. It is defined as the clinical practice of measuring specific drugs at designated intervals to maintain a constant concentration in a patient's bloodstream, thereby optimizing individual dosage regimens [2]. TDM is not merely a laboratory measurement; it is a comprehensive process that integrates pharmacokinetic (what the body does to the drug) and pharmacodynamic (what the drug does to the body) principles with clinical observation. The primary rationale for TDM is applied to drugs with a narrow therapeutic index (NTI), where the margin between effective and toxic concentrations is small, and for drugs where the correlation between dose and clinical effect is poor, but the correlation between plasma concentration and effect is strong [3]. Classic examples include aminoglycoside antibiotics, anticonvulsants like phenytoin and valproic acid, cardioactive drugs such as digoxin, immunosuppressants (e.g., tacrolimus,

cyclosporine), and specific psychotropic medications.

Traditionally, the TDM process was often fragmented. A clinician would order a drug assay based on clinical suspicion of toxicity or lack of efficacy. The clinical laboratory would report a numerical serum concentration, and the clinician, often without specialized training in pharmacokinetics, would make a dosing adjustment decision, frequently relying on empirical rules of thumb. This disjointed approach presented significant limitations. The isolated plasma concentration value is, in itself, clinically meaningless without proper interpretation. Critical factors such as the exact timing of the blood sample relative to the last dose, the patient's clinical status (e.g., renal/hepatic function, albumin levels), potential drug-drug interactions, and adherence to the prescribed regimen are all essential for accurate interpretation [4]. A value reported as "high" could be appropriate for a patient at a specific time post-dose or could indicate toxicity; a "therapeutic" value might be inadequate if sampled at the wrong time or if the patient has a unique pharmacokinetic profile.

For decades, the pharmacist's role was perceived primarily as a dispenser of medications. However, the profession has undergone a profound evolution, transitioning from a product-centered to a patient-centered paradigm. Contemporary clinical pharmacists are experts in pharmacotherapy, possessing deep knowledge of pharmacokinetics, pharmacodynamics, pharmacology, and therapeutics. Their education and training are uniquely suited to bridge the critical gap between the raw laboratory data of TDM and its effective clinical application [5]. They are positioned to interpret drug concentration results within the full clinical context of the patient, apply complex pharmacokinetic calculations to predict individualized dosing regimens, monitor for

efficacy and toxicity, counsel patients on adherence, and serve as a vital drug information resource for the interdisciplinary team.

This expanded role is not merely theoretical but is increasingly recognized and formalized in various healthcare settings, from intensive care units and transplant centers to outpatient anticoagulation and infectious disease clinics. The central thesis of this discourse is that the active, integrated involvement of pharmacists in the TDM process—from test indication and sampling to interpretation, dosage adjustment, and follow-up—significantly enhances the quality and safety of patient care, leading to measurably superior clinical outcomes. This involvement transforms TDM from a reactive, data-reporting activity into a proactive, patient-specific management tool. The potential benefits are multifold: improved attainment of therapeutic goals, reduced incidence of drug toxicity, shortened hospital length of stay, decreased overall healthcare costs, and enhanced patient education and adherence [6].

The evidence supporting pharmacist-driven TDM services has been accumulating over the past three decades. Studies have demonstrated that pharmacists can improve the appropriate utilization of TDM assays, reduce the frequency of erroneous or unnecessary blood draws, and increase the proportion of drug concentrations within the therapeutic range. More importantly, these process improvements translate into tangible clinical benefits, such as lower rates of nephrotoxicity with aminoglycosides, fewer seizures in patients on antiepileptics, and more stable immunosuppression in transplant recipients [7]. Furthermore, pharmacists contribute to the economic sustainability of healthcare by preventing ADRs and optimizing drug expenditure. As healthcare systems worldwide grapple with the challenges of an aging population, polypharmacy, and rising costs, the value of integrating pharmacist expertise into critical processes like TDM becomes increasingly apparent [8].

## 2. The Evolving Role of the Pharmacist: From Dispenser to Clinical Decision-Maker

The integration of pharmacists into the TDM process is a direct consequence of the evolution of pharmacy practice. The traditional apothecary model, focused solely on the accurate preparation and dispensing of medicines, has been progressively supplanted by a clinical model where the pharmacist is an essential member of the patient care team. This shift was driven by factors including increased complexity of drug therapy, recognition of medication errors as a major cause of

patient harm, and a growing body of evidence demonstrating the positive impact of clinical pharmacy services. In the context of TDM, the pharmacist's unique skill set is indispensable. Their expertise encompasses a detailed understanding of a drug's absorption, distribution, metabolism, and excretion (ADME) properties. They are trained to apply pharmacokinetic principles—such as clearance, volume of distribution, and half-life—to real patient data, using both simple linear methods and sophisticated population pharmacokinetic modeling software to design personalized regimens [9]. This scientific foundation allows them to move beyond simply identifying whether a level is "high" or "low" and instead answer the more clinically pertinent questions: *Why* is the level abnormal? What is the predicted concentration at a different time point? What precise dose adjustment is most likely to achieve the target concentration at the desired time? And what is the anticipated clinical effect of this adjustment? This analytical approach ensures that TDM is used as a dynamic tool for guiding therapy, not just a static snapshot for diagnostic confirmation.

## 3. Optimizing the TDM Process: From Test Indication to Follow-Up

Pharmacist involvement enhances every step of the TDM cycle, creating a more efficient, accurate, and clinically relevant process. The first critical intervention point is at the stage of test indication and timing. Inappropriate or poorly timed TDM requests are a common source of wasted resources and misleading information. Pharmacists, through their review of medication orders and patient charts, can identify the optimal timing for sample collection based on the drug's pharmacokinetics (e.g., trough levels for aminoglycosides, pre-dose and post-dose levels for phenytoin). They ensure that steady-state conditions have been achieved (typically after 4-5 half-lives) before sampling, unless assessing a loading dose or suspected toxicity [10]. By providing education to nursing and medical staff on proper sampling protocols, pharmacists directly reduce the number of uninterpretable levels, thereby increasing the utility and cost-effectiveness of the TDM service.

Once a valid drug concentration result is available, the pharmacist's role in interpretation and dosage regimen design becomes paramount. The pharmacist does not view the number in isolation. They perform a comprehensive assessment, integrating the plasma concentration with the patient's clinical data: diagnosis and therapeutic goal, renal and hepatic function, serum albumin, fluid status, presence of interacting medications,

and evidence of efficacy or toxicity. For instance, a "subtherapeutic" vancomycin trough in a patient with improving signs of infection and normal renal function may not require aggressive dose escalation, whereas the same level in a critically ill patient with persistent fever might. Pharmacists utilize pharmacokinetic equations to calculate patient-specific parameters like creatinine clearance (used to estimate drug clearance for renally eliminated drugs) and then apply these to recommend precise dosage adjustments. They can simulate different dosing scenarios (e.g., changing the dose, the interval, or both) to predict which regimen is most likely to achieve the target concentration, thereby moving from trial-and-error dosing to a predictive, scientifically-grounded approach [11]. This tailored recommendation is then communicated to the prescriber, often through a formal consultation note in the medical record or via direct discussion, facilitating informed decision-making.

#### 4. Enhancing Clinical Outcomes and Patient Safety

The most significant impact of pharmacist-led TDM is on direct patient outcomes, particularly for drugs with a narrow therapeutic index. Robust evidence across various drug classes and clinical settings demonstrates this benefit. In antimicrobial therapy, for example, pharmacist management of aminoglycoside (gentamicin, tobramycin) and vancomycin TDM is considered a standard of care. Multiple studies have shown that pharmacist intervention leads to a higher percentage of levels within the therapeutic range, a faster time to achieve therapeutic levels, and a consequent reduction in nephrotoxicity and ototoxicity associated with these agents [12, 13]. This is especially crucial in critically ill patients whose rapidly changing renal function makes dosing particularly challenging. For vancomycin, with its concentration-dependent efficacy and toxicity profile, pharmacist pharmacokinetic dosing has been linked to improved clinical cure rates for serious methicillin-resistant *Staphylococcus aureus* (MRSA) infections while mitigating the risk of acute kidney injury [14].

In the realm of transplant medicine, where lifelong immunosuppression is required to prevent graft rejection, TDM of drugs like tacrolimus and cyclosporine is mandatory. These drugs exhibit immense inter- and intra-patient variability and are subject to numerous drug and food interactions. Pharmacist-managed TDM programs in transplant clinics have consistently demonstrated superior outcomes. They are associated with a greater

proportion of levels within the target range, lower rates of acute rejection episodes, and reduced incidence of drug-related toxicities such as nephrotoxicity, neurotoxicity, and post-transplant diabetes mellitus [15]. The pharmacist's ongoing vigilance in monitoring for interactions (e.g., with azole antifungals or macrolide antibiotics) and adjusting doses preemptively is a key component of long-term graft and patient survival.

For antiepileptic drugs (AEDs) like phenytoin, which follows non-linear (saturable) pharmacokinetics, small dose changes can lead to disproportionately large changes in serum concentration. Inpatient and outpatient pharmacist involvement in phenytoin TDM has been shown to improve seizure control, minimize central nervous system toxicity (ataxia, nystagmus, drowsiness), and reduce the frequency of unnecessary level measurements and inappropriate dosing [16]. Similarly, in cardiology, pharmacist management of digoxin therapy—a drug with a very narrow therapeutic window and significant toxicity in the elderly or those with renal impairment—can prevent life-threatening arrhythmias and hospital admissions due to toxicity while ensuring adequate rate control in conditions like atrial fibrillation [17].

#### 5. Improving Patient Education, Adherence, and Therapeutic Alliance

A frequently overlooked but vital component of successful TDM is patient understanding and adherence. A drug level is profoundly affected by whether the patient is taking the medication as prescribed. Pharmacists are the most accessible healthcare professionals trained in medication counseling. Their involvement in TDM provides a natural opportunity for reinforced patient education. When discussing a dose adjustment based on a TDM result, the pharmacist can explain the reason for the change in the context of the patient's condition, reinforce the importance of adherence to the timing and schedule of doses, and discuss potential side effects to watch for [18]. This is particularly important for drugs like tacrolimus, where consistency with regards to food intake is critical, or for phenytoin, where missed doses can precipitate breakthrough seizures. By demystifying the process of blood tests and dose changes, pharmacists empower patients, fostering a stronger therapeutic alliance. Improved adherence, in turn, leads to more stable drug concentrations, better disease control, and more meaningful TDM results, creating a positive feedback loop that enhances overall treatment success.

## 6. Facilitating Interdisciplinary Collaboration and Communication

Effective TDM is inherently a collaborative endeavor. It requires seamless communication between the prescribing physician, the nursing staff obtaining the blood sample, the laboratory personnel performing the assay, and the professional interpreting the result. The clinical pharmacist often serves as the crucial hub in this network. They translate laboratory data into clinical recommendations, communicate these clearly to the prescriber, and provide guidance to nursing on follow-up sampling times. By documenting their assessments and recommendations in the patient's health record, they create a transparent and auditable trail of the therapeutic decision-making process [19]. This structured communication reduces errors, prevents misunderstandings, and ensures continuity of care, especially during handoffs between different healthcare providers or upon transfer between care settings (e.g., from ICU to general ward). The pharmacist thus acts as an integrator of information, enhancing team coherence and ensuring that the collective expertise of the healthcare team is effectively applied to the patient's drug therapy.

## 7. Economic Impact and Healthcare System Benefits

Beyond clinical efficacy and safety, pharmacist involvement in TDM generates substantial economic benefits for healthcare systems. This economic impact is achieved through multiple mechanisms. First, by optimizing dosing, it reduces drug waste from ineffective sub-therapeutic dosing and prevents the high costs associated with managing ADRs from suprathreshold dosing. Treating drug-induced nephrotoxicity or neurotoxicity often requires extended hospitalization, additional diagnostic tests, and supportive therapies, all of which carry significant cost burdens [20]. Second, by ensuring proper test indication and timing, pharmacists improve the efficiency of laboratory resource utilization, reducing the number of unnecessary or uninterpretable drug assays. Third, improved clinical outcomes—such as faster resolution of infection, reduced graft rejection, or better seizure control—directly translate into shorter hospital lengths of stay, reduced readmission rates, and decreased need for expensive rescue therapies [21]. Pharmacist-driven TDM services in outpatient clinics for conditions like epilepsy or transplantation can prevent costly emergency department visits and hospital admissions. While

establishing a clinical pharmacy TDM service requires an initial investment in personnel, the return on investment is consistently positive, with studies showing significant cost savings or cost-neutrality accompanied by improved quality of care [22]. In an era of constrained healthcare budgets, services that both improve outcomes and reduce net costs are of paramount value.

## 8. Challenges, Barriers, and Future Directions

Despite the compelling evidence, the full integration of pharmacists into TDM services is not without challenges. Barriers exist at systemic, professional, and technological levels. Systemic barriers include the lack of formal recognition and reimbursement for clinical pharmacy cognitive services in many healthcare payment models. Pharmacists' time spent on complex TDM interpretation and consultation is often not directly billable, making it difficult for institutions to justify dedicated FTEs for this role [23]. Professional barriers may include residual territorial attitudes among some physician groups and a lack of awareness among hospital administrators of the pharmacist's potential contribution beyond dispensing. Furthermore, not all pharmacists possess the advanced training or confidence required for high-level pharmacokinetic consultation, highlighting the need for ongoing education and specialized residency training in pharmacotherapy or pharmacokinetics [24]. Technologically, while many hospital electronic health records (EHRs) have integrated laboratory data, they often lack sophisticated clinical decision support (CDS) tools for TDM. The future lies in further leveraging technology. Advanced CDS systems, potentially powered by artificial intelligence and machine learning, could integrate real-time patient data (creatinine, weight, concomitant medications) with TDM results to provide dosing recommendations [25]. However, these systems will not replace the pharmacist; rather, they will serve as powerful tools to enhance their efficiency and accuracy, allowing them to manage larger patient panels and focus on the most complex cases. The continued expansion of pharmacogenomics, which provides insights into a patient's innate drug metabolism capacity, will also intersect profoundly with TDM. Pharmacists are ideally positioned to interpret both genotypic and phenotypic (concentration) data to achieve an even more refined level of personalized dosing [26]. Future practice models will likely see the pharmacist as the synthesizer of multi-omic and therapeutic data, guiding precision pharmacotherapy in its most advanced form.

## 9. Conclusion

Therapeutic Drug Monitoring represents a critical junction in patient care where laboratory science must be effectively translated into clinical action. The involvement of pharmacists in this process is not a mere ancillary service but a fundamental enhancement that addresses the core limitations of traditional TDM practice. By applying their expertise in pharmacokinetics, pharmacotherapy, and patient care, pharmacists transform TDM from a passive monitoring tool into an active, patient-specific management strategy. The evidence is clear and multifaceted: pharmacist involvement leads to more accurate and appropriately timed drug assays, more precise and individualized dosing recommendations, and ultimately, to superior clinical outcomes across a spectrum of serious diseases. These outcomes include improved efficacy of antimicrobial and immunosuppressive regimens, reduced drug-related toxicity, enhanced patient adherence and understanding, and more effective interdisciplinary collaboration. Concurrently, this model of care promotes healthcare system efficiency by reducing medication errors, preventing adverse drug events, optimizing resource use, and containing costs.

As healthcare continues to advance towards greater personalization and faces increasing complexity, the role of the pharmacist as the medication therapy expert will only become more indispensable. Overcoming the existing barriers to implementation—through advocacy for sustainable reimbursement models, interdisciplinary education, and technological innovation—is essential to fully realize the potential of pharmacist-driven TDM. Ultimately, the integration of pharmacists into the TDM team is a demonstrably effective strategy for achieving the paramount goals of modern medicine: delivering safer, more effective, and more efficient care to every patient. The consistent correlation between their involvement and improved clinical outcomes firmly establishes the pharmacist as a cornerstone of high-quality Therapeutic Drug Monitoring and, by extension, of optimal pharmacotherapy.

### Author Statements:

- **Ethical approval:** The conducted research is not related to either human or animal use.
- **Conflict of interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper

- **Acknowledgement:** The authors declare that they have nobody or no-company to acknowledge.
- **Author contributions:** The authors declare that they have equal right on this paper.
- **Funding information:** The authors declare that there is no funding to be acknowledged.
- **Data availability statement:** The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

## References

- [1] Kanda Y. Investigation of the freely available easy-to-use software EZR for medical statistics. *Bone Marrow Transpl.* 2013;48:452–8.
- [2] Houot M, Pilmis B, Thepot-Seegers V, Suard C, Potier C, Postaire M, et al. Aminoglycoside use in a pediatric hospital: there is room for improvement—a before/after study. *Eur J Pediatr.* 2016;175:659–65.
- [3] Yamada T, Fujii S, Shigemi A, Takesue Y. A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity. *J Infect Chemother.* 2021;26:256–61.
- [4] Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis.* 2016;62:e51–77.
- [5] Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, et al. *Pseudomonas aeruginosa*: resistance and therapeutic options at the turn of the new millennium. *Clin Microbiol Infect.* 2007;13:560–78.
- [6] Nakatani S, Ohara T, Ashihara K, Izumi C, Iwanaga S, Eishi K, et al. JCS 2017 guideline on prevention and treatment of infective endocarditis. *Circ J.* 2019;83:1767–809.
- [7] Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. *Clin Infect Dis Infect Dis Soc Am.* 2023;ciad428.
- [8] Pitiriga V, Dimitroulia E, Saroglou G, Tsakris A. The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role? *Expert Rev Anti Infect Ther.* 2017;15:947–54.
- [9] Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2011;52:e56–93.
- [10] Roger C, Louart B, Elotmani L, Barton G, Escobar L, Koulenti D, et al. An international survey on

- aminoglycoside practices in critically ill patients: the AMINO III study. *Ann Intensive Care*. 2021;11:49.
- [11] Imani S, Alffenaar JW, Cotta MO, Daveson K, van Hal S, Lau C, et al. Therapeutic drug monitoring of commonly used anti-infective agents: a nationwide cross-sectional survey of Australian hospital practices. *Int J Antimicrob Agents*. 2020;56:106180.
- [12] Picard W, Bazin F, Clouzeau B, Bui HN, Soulat M, Guilhon E, et al. Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock. *Antimicrob Agents Chemother*. 2014;58:7468–74.
- [13] Delgado V, Ajmone Marsan N, De Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC guidelines for the management of endocarditis. *Eur Heart J*. 2023;44:3948–4042.
- [14] Nauriyal V, Rai SM, Joshi RD, Thapa BB, Kaljee L, Prentiss T, et al. Evaluation of an antimicrobial stewardship program for wound and burn care in three hospitals in Nepal. *Antibiot (Basel)*. 2020;9:914.
- [15] Sandaradura I, Alffenaar JW, Cotta MO, Daveson K, Day RO, Van Hal S, et al. Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: availability, performance and barriers to implementation. *Br J Clin Pharmacol*. 2022;88:669–79.
- [16] Cook PP, Gooch M. Long-term effects of an antimicrobial stewardship programme at a tertiary-care teaching hospital. *Int J Antimicrob Agents*. 2015;45:262–7.
- [17] Buckman SA, Forrester JD, Bessoff KE, Parli SE, Evans HL, Huston JM. Surgical Infection Society Guidelines: 2022 updated guidelines for antibiotic use in open extremity fractures. *Surg Infect (Larchmt)*. 2022;23:817–28.
- [18] Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;49:1–45.
- [19] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract*. 2012;120:c179–84.
- [20] Martinez-Salgado C, López-Hernández FJ, López-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. *Toxicol Appl Pharmacol*. 2007;223:86–98.
- [21] Huang X, Liu YX, Lao JH, Cao J, Li X, Yao WB. The incidence of acute kidney injury in hospitalised patients receiving aminoglycoside antibiotics: a retrospective study. *Eur Rev Med Pharmacol Sci*. 2022;26:3718–25.
- [22] Katagiri H, Mitsuboshi S, Katagiri H, Tsugita M. Antimicrobial therapeutic drug monitoring performance rate in Niigata: evaluation between performance rate and relevant factors. *Japanese J Environ Infections*. 2018;33:62–6.
- [23] Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. *Antimicrob Agents Chemother*. 1999;43:1549–55.
- [24] McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglycoside-induced nephrotoxicity in children. *Pediatr Nephrol*. 2017;32:2015–25.
- [25] Jenkins A, Thomson AH, Brown NM, Semple Y, Sluman C, MacGowan A, et al. Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. *J Antimicrob Chemother*. 2016;71:2754–9.
- [26] Nežić L, Derungs A, Bruggisser M, Tschudin-Sutter S, Krähenbühl S, Haschke M. Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy. *Eur J Clin Pharmacol*. 2014;70:829–37.